BBS6 Inhibitors
BBS6 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Bardet-Biedl Syndrome protein 6 (BBS6). BBS6 is one of the critical components of the BBSome, a protein complex that plays a significant role in the trafficking of cargo proteins to the primary cilia. Primary cilia are microtubule-based organelles that serve as cellular signaling hubs, coordinating a wide range of signaling pathways, including those involved in cellular development and homeostasis. BBS6, as part of the BBSome complex, assists in the assembly and stabilization of this protein structure, facilitating the proper functioning of cilia. By inhibiting BBS6, these inhibitors disrupt the normal functioning of the BBSome, leading to altered ciliary signaling and impairments in the associated cellular processes.
The chemical structure of BBS6 inhibitors varies but generally consists of a scaffold capable of interacting with the BBS6 protein at its key functional domains. These inhibitors are designed to bind to specific regions on the BBS6 protein that are involved in its interaction with other components of the BBSome. By blocking these interactions, BBS6 inhibitors effectively prevent the formation or functionality of the BBSome, resulting in defective intracellular transport processes, particularly those linked to the ciliary membrane. The development of BBS6 inhibitors involves understanding the structural biology of BBS6 and its role within the BBSome, providing a blueprint for designing molecules that can selectively hinder its function. This disruption has broader implications for studying the roles of cilia in cellular organization and signaling pathways, providing a window into understanding the underlying biochemical mechanisms that depend on ciliary function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may downregulate BBS6 expression by inhibiting histone deacetylase activity, leading to increased acetylation of histones and a less compact chromatin structure at the BBS6 gene, which can suppress its transcription initiation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could decrease BBS6 expression by incorporating into DNA and RNA, subsequently inhibiting DNA methyltransferase. This can result in hypomethylation of the BBS6 gene promoter, reducing the transcriptional repression of this gene. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may reduce BBS6 expression by blocking histone deacetylase enzymes, which would otherwise remove acetyl groups from histone proteins, potentially leading to a more relaxed chromatin structure at the BBS6 gene locus and suppression of its expression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 has the potential to decrease BBS6 gene expression through inhibition of DNA methyltransferase, promoting DNA demethylation at the BBS6 promoter region, which could result in transcriptional silencing. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine may lead to BBS6 expression reduction by inhibiting DNA methyltransferase, causing DNA hypomethylation. This hypomethylation at the BBS6 gene locus may decrease the binding of methyl-CpG-binding proteins and transcriptional repressors, leading to reduced BBS6 transcription. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A can inhibit BBS6 transcription by binding to the G-C-rich sequences in the BBS6 promoter region, obstructing the binding site for specific transcription factors essential for BBS6 expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D may inhibit BBS6 mRNA synthesis by intercalating into DNA at the transcription initiation complex, obstructing RNA polymerase movement along the DNA template and thereby preventing BBS6 transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid could downregulate BBS6 expression through its role as a ligand for retinoic acid receptors, which can bind to retinoic acid response elements in the BBS6 gene promoter and repress its transcriptional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit BBS6 expression by specifically binding to the mTOR complex, which plays a critical role in cell growth and protein synthesis; inhibition of this pathway can lead to a reduction in BBS6 protein levels. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride can downregulate BBS6 expression by inhibiting GSK-3, which may alter downstream transcription factor activity and reduce transcriptional activation of the BBS6 gene. | ||||||